Frances Stocks Allen

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom
Profile Experience

Frances Stocks Allen advises leading life sciences companies and industry investors on a range of technology-based commercial matters, including complex licenses, collaborations, acquisitions, and divestments.

Ms. Stocks Allen provides sophisticated commercial, transactional, and regulatory advice to multinational, European, and US-based companies and investors in the biotech, pharmaceutical, and medical devices sectors. Her work includes licensing and other complex commercial and intellectual property arrangements. She brings particular experience in relation to UK and EU regulations and data privacy, including the General Data Protection Regulation (GDPR).

Ms. Stocks Allen helps clients anticipate and navigate legal challenges by drawing on her secondment experience, including in-house at Allergan and at the firm’s Silicon Valley office. She provides pragmatic, commercially driven, and digestible advice to help clients achieve their business objectives and strategic goals.

Ms. Stocks Allen frequently writes on topics related to legal issues in the life sciences sector, including for industry publications such as Law360 and Privacy Laws & Business.

Ms. Stocks Allen is a member of the firm’s Mentoring Committee, and previously served as a global leader of the Women’s Leadership Group.

Ms. Stocks Allen was identified as a Legal 500 Rising Star 2020-2022 in Life Sciences and Healthcare: "Frances Stocks Allen stands out as a rising star. She is highly knowledgeable and always available, with a pragmatic approach, good business acumen and short response times." She was also part of a team of Latham lawyers who received TrustLaw’s Lawyer of the Year Award — an honor that recognizes outstanding pro bono service.

 Ms. Stocks Allen’s experience includes advising:

  • Swedish Orphan Biovitrum AB (publ) (Sobi™) on a variety of matters, including:
    • Its strategic licensing and collaboration agreement with Apellis Pharmaceuticals Inc. for co-development and exclusive ex-US commercialisation rights for systemic pegcetacoplan, with a deal value of approximately US$1.2 billion
    • Its strategic licensing agreement with Selecta Biosciences for SEL-212, a phase-3 ready therapy for the treatment of chronic refractory gout, with a deal value of approximately US$730 million
    • Its acquisition of rights to Synagis in the US from AZ and the right to participate in future earnings of the candidate drug MEDI8897 in the US for US$1.5 billion

  • Oasmia Pharmaceutical on its global strategic partnership for the development and commercialization of its proprietary anticancer product Apealea with Elevar Therapeutics, with a deal value of approximately US$698 million
  • GSK on a variety of matters, including:
    • Various early-stage collaboration, development, and supply arrangements
    • The divestment of its Prevacid 24HR business to Perrigo Company
    • The divestment of assets relating to the Bialcol and Cibalgina brands in Italy to Vemedia
    • The divestment of five over-the-counter dermatology brands and one pediatric cough remedy brand to the STADA Group
    • The divestment of certain North American consumer health assets to Crown Laboratories
  • A leading DNA sequencing and cancer diagnostic company in connection with its strategic JV with the private equity investment arm of a multinational holding conglomerate
  • A leading gene editing company in the negotiation of a research and collaboration agreement with a research institute in respect of proprietary technology for the development of gene therapies
  • Frontier Medicines, Corp. on the data privacy aspects of its global partnership with AbbVie to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein target
  • KKR on its €50 million investment in Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges
  • Acino on its acquisition of certain pain management, gastroenterology, cardiovascular, and respiratory products from Takeda Pharmaceuticals
  • Theramex on various matters, including:
    • Its foundational acquisition of the Teva women’s health business for US$703 million
    • Its acquisition of certain assets related to the ZOELY contraceptive pill from Merck Sharp & Dohme B.V.
    • Its acquisition of certain assets related to the Systen, Systen Conti, and Evorel products from Janssen Pharmaceutica NV
  • Allergan in connection with its divestment of its global generic pharmaceuticals business and the rights to certain branded products to Teva for US$40.6 billion
  • A leading US medical devices company on all aspects of its UK launch
  • Various pharmaceutical and medical technology companies on regulatory and compliance matters, including the conduct of clinical trials in the EU and UK and GDPR
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.